Start with the exact research question
“NAD research” is a broad category, not a single body of interchangeable results. A useful reading begins with a more precise question: which substance was given, by which route, to whom, for how long, and what changed? Keep those five details beside a product claim. They help distinguish a relevant study from an impressive-looking reference that answers a different question.
NAD+ is the molecule at the center of this discussion. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors studied as ways to influence NAD metabolism. A capsule containing a precursor and an infusion containing NAD+ should occupy separate rows in your comparison. Sharing a biological pathway does not make two products interchangeable.
Two trials worth reading closely
Martens and colleagues studied oral NR in a randomized, double-blind crossover trial in healthy middle-aged and older adults. The six-week treatment periods showed effects on NAD metabolism. The authors described blood-pressure and arterial-stiffness findings as exploratory hypotheses for larger studies. That is a reason to investigate further, not a basis for advertising a proven cardiovascular treatment. [1]
Yoshino and colleagues studied NMN for ten weeks in 25 postmenopausal women with prediabetes and overweight or obesity. Muscle insulin sensitivity improved, but that finding did not extend to every metabolic measure. The study did not establish diabetes prevention, benefits in men, or a general anti-aging effect. Its narrow population is part of the result, not a footnote to discard. [2]
Separate a finding from a purchasing decision
Neither trial is a head-to-head comparison of a retail NR bottle with an NAD injection service. Neither provides a reliable ranking of clinics. If a provider cites one of these papers, match the cited ingredient and route to the actual offer before treating the reference as support for that offer. A familiar molecule name in the abstract is only the beginning of that check.
Next, identify the endpoint. A change in a laboratory measurement, a change in a physiological test and a change in day-to-day symptoms are different claims. Ask which was measured directly. Be equally attentive to findings that did not change; a summary that mentions only the favorable result can make a limited study sound much broader than it is.
A practical evidence checklist
Open the full paper where possible. Look for a comparison group, the number of participants who completed the study, the duration, the outcomes chosen in advance, adverse events and funding disclosures. Small studies can generate useful signals. They also leave important uncertainty about durability, uncommon harms and whether results transfer to other people.
For a provider conversation, write down one outcome you actually care about and ask which human trial measured it using the offered formulation. If the answer is a testimonial or a general mechanism, label it accordingly. Our ingredient explorer organizes products by ingredient and route; it does not turn early findings into a treatment recommendation. The two studies discussed here are illustrative primary studies, not an exhaustive review of all NAD research.
Sources
Educational editorial analysis by NAD Atlas. No firsthand treatment experience or clinical review is implied.